I had a fascinating chat with Hashan de Silva, also available on Spotify and iTunes.
Hashan covers his new fund KP Rx and his extensive background in healthcare, starting with a stint in medicine and his first job in industry commercialising drugs at Eli Lilly.
At the time Eli Lilly was launching Byetta, their first GLP-1.
There have been many drugs found to reduce weight, but these all turned out to cause serious problems, from heart attacks to meth addiction.
The curious thing about GLP-1s is that this time around, the catastrophic side effects have not shown up. In fact, the opposite: long term trials show significant improvements in health.
Hashan’s early investors include some of Australia’s most successful healthcare entrepreneurs: Patrick Davies (Chairman of Neuren), Lou Panaccio (director of Sonic) and Dr Glenn Haifer.
Hashan is on the board of Curvebeam AI which is entering a pivotal moment as the firm expands its installed base ahead of software modules set to be released in CY2025.
He is also a director of Syntara, a local drug development company.
I’ve always had a soft spot for Syntara as they do their chemistry in house and design their own drugs in Sydney, where they are world leaders in oxidase enzyme chemistry. Quite refreshing compared to the repurposed, reformulated or otherwise unwanted drugs that seem to make it onto the ASX.
Syntara has four programs in the clinic:
- Myelofibrosis: Their main program targets this rare bone marrow cancer. Results from this trial will read out later this year, and if successful, it would be the first disease-modifying treatment for the condition. Transactions in this space have been over US$1.5 billion, while Syntara is a ~US$45 million company.
- Myelodysplastic Syndromes (MDS): Running Phase 2 trials funded by the German government.
- Parkinson's Disease: A Phase 2 program funded by a UK charity.
- Scar Prevention: A Phase 2-stage program in collaboration with the renowned Professor Fiona Wood in Perth.
Recent transactions in myelofibrosis
This is one of our positions I haven’t talked much about - mostly as there will soon be a binary readout which will move it significantly in either direction.
We then discussed to Skin2Neuron, which has apparently cured a small number of dogs with Alzheimers, by taking cells from hair follicles, inducing them into a stem-cell state with Yamanaka factors, then implanting them in the brain where they have self-organised and led to visible recovery in memory function.
Dogs are the best animal model for Alzheimers as they develop it naturally. Most animals need to have the disease state induced or engrafted, and are thus frustratlingly limited, albeit most would argue better than nothing.
Hopefully one day this kind of work is done with digital models of human biology and we can spare the mammals.
Finally, we do a quick round on some local companies like Clarity and Telix.
I am sure you’ll find this one interesting!
Michael
If you'd like to invest with us, you can access our investment portal and fund documentation through the button above.
Or simply reply to this email and we'll be in touch.
Disclaimer
The information in this note has been prepared and issued by Frazis Capital Partners Pty Ltd ABN 16 625 521 986 as a corporate authorised representative (CAR No. 1263393) of Frazis Capital Management Pty Ltd ABN 91 638 965 910 AFSL 521445. The Frazis Fund is open to wholesale investors only, as defined in the Corporations Act 2001 (Cth). The Company is not authorised to provide financial product advice to retail clients and information provided does not constitute financial product advice to retail clients.
The information provided is for general information purposes only, and does not take into account the personal circumstances or needs of investors. The Company and its directors or employees or associates will use their endeavours to ensure that the information is accurate as at the time of its publication. Notwithstanding this, the Company excludes any representation or warranty as to the accuracy, reliability, or completeness of the information contained on the company website and published documents.
The past results of the Company’s investment strategy do not necessarily guarantee the future performance or profitability of any investment strategies devised or suggested by the Company.
The Company, and its directors or employees or associates, do not guarantee the performance of any financial product or investment decision made in reliance of any material in this document. The Company does not accept any loss or liability which may be suffered by a reader of this document.
